Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Businesses face increasing pressure from their investors, customers, employees, regulators, and other stakeholders to promote their ESG goals in the transition to a more sustainable economy. Many businesses look to effect more impactful changes by addressing systemic issues through collaboration with other participants in their industry. This, however, creates risks that require careful management to avoid running afoul of competition laws.
Many competition enforcers have provided guidance to help companies resolve this tension and encourage lawful collaboration at the industry level, but others have recognized that there is no sustainability exception to antitrust laws and declined to provide guidance to help businesses navigate the intersection of ESG and competition laws. Still others have threatened and even initiated enforcement action against “climate cartels” on theories that sound in antitrust law.
Businesses engaged in ESG and sustainability efforts need to keep up-to-date with the changing enforcement and regulatory landscape, understand the growing body of guidance across jurisdictions, and distinguish the reality from the rhetoric of some enforcers to fully understand their antitrust risks and ensure that they remain compliant with competition laws.
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
While country risk cannot be avoided in cross-border transactions entirely, it can be effectively mitigated through careful transaction structuring and tailored contractual protections.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023